Zobrazeno 1 - 10
of 21
pro vyhledávání: ''
Autor:
Mario Giuliano, Emilia Montagna, Diego D'Agostino, Sabino De Placido, Giuseppe Cancello, Monica Plaitano, Giuseppe Di Lorenzo, Michele De Laurentiis, Antonio Giordano
Publikováno v:
Breast Cancer Research : BCR
INTRODUCTION: We performed a retrospective analysis of HER2-overexpressing metastatic breast cancer patients to describe clinical outcomes of those who, despite progression of the disease (PD), maintained trastuzumab for multiple chemotherapy lines.
Publikováno v:
Breast Cancer Research : BCR
Introduction Protein tyrosine kinase 6 (PTK6) is a non-receptor tyrosine kinase that is highly expressed in Human Epidermal Growth Factor 2+ (Her2+) breast cancers. Overexpression of PTK6 enhances anchorage-independent survival, proliferation, and mi
Autor:
Marianne G. Rots, Nadine Martinet, Michel van Kruchten, G.A.P. (Geke) Hospers, Fahimeh Falahi
Publikováno v:
Breast Cancer Research : BCR
DNA methylation and histone modifications are important epigenetic modifications associated with gene (dys)regulation. The epigenetic modifications are balanced by epigenetic enzymes, so-called writers and erasers, such as DNA (de)methylases and hist
Autor:
Maria García-Aranda, Teresa Téllez, Maria Luisa Hortas, Alfonso Serrano, Maximino Redondo, Maria J. Roldan, Martin E. Gleave, Miguel Morell
Publikováno v:
Breast Cancer Research : BCR
Introduction Overexpression of the apoptosis-related protein clusterin is associated with breast cancer development and tumor progression. We describe the use of clusterin-specific antisense oligonucleotides and antibodies to sensitize breast carcino
Autor:
Kosei Hirakawa, Naoki Aomatsu, Tsutomu Takashima, Katsumi Ikeda, Tetsuro Ishikawa, Masakazu Yashiro, Shinichiro Kashiwagi, Yoshinari Ogawa
Publikováno v:
Breast Cancer Research : BCR
Introduction Triple-negative breast cancer (TNBC), which is characterized by negativity for estrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 (HER2), is a high risk breast cancer that lacks specific targets for tre
Autor:
A. Rocca, Elisabetta Munzone, Giuseppe Renne, Aron Goldhirsch, Giuseppe Curigliano, Giuseppina Bonizzi, Franco Nolè
Publikováno v:
Breast Cancer Research
Introduction The amounts of estrogen receptor (ER) and progesterone receptor (PgR) in a primary tumor are predictive of the response to endocrine therapies of breast cancer. Several patients with ER-positive primary tumors relapse after adjuvant endo
Autor:
Jennifer M. Giltnane, Harriet M. Kluger, Yasmine Nadler, Christopher B. Moeder, David L. Rimm, Robert L. Camp, Yuval Kluger
Publikováno v:
Breast Cancer Research : BCR
Introduction Bcl-2 antanogene-1 (Bag-1) binds the anti-apoptotic mediator Bcl-2, and enhances its activity. Bcl-2 and Bag-1 are associated with chemotherapy resistance in cancer cells. Drugs that target Bcl-2 are currently in clinical development. Th
Autor:
Nicholas J. Donato, Anupama Pal
Publikováno v:
Breast Cancer Research : BCR
Key mediators of signaling pathways in breast cancer involve post-translational protein modification, primarily mediated through phosphorylation and ubiquitination. While previous studies focused on phosphorylation events, more recent analysis sugges
Autor:
Kathleen C. Flanders, JoAnne Zujewski, Anika Vaughn-Cooke, Lalage M. Wakefield, Michael Eckhaus, Ronald A. Lubet
Publikováno v:
Breast Cancer Research
Using a carcinogen-initiated rat model of mammary tumorigenesis, we tested the hypothesis that transforming growth factor (TGF)-betas are useful biomarkers of chemopreventive efficacy in the breast. The chemopreventive agents tested were tamoxifen an
Autor:
Steven A. Narod, Cezary Cybulski, Robert Chrzan, Jan Lubinski, Tomasz Huzarski, Jacek Gronwald, Andrea Eisen, Paweł Blecharz, Tomasz Byrski, Małgorzata Foszczyńska-Kłoda, Rebecca Dent, E. Marczyk
Publikováno v:
Breast Cancer Research : BCR
Introduction The purpose of this investigation was to evaluate the efficacy of cisplatin chemotherapy in BRCA1 mutation carriers with metastatic breast cancer. Methods In a phase II, open-label study, 20 patients with metastatic breast cancer who car